Fig. 7

The tumor targeting ability of cRGD-NPs and the antitumor efficiency of BAF312@cRGD-CaP-NPs in vivo. a Upper: After intravenous injection for 2, 12, 24 and 96 h, the distribution of Dir@CaP-NPs and Dir@cRGD-CaP-NPs in MDA-MB-231 tumor-bearing nude mice (Dir dose is 1 μg/mL) (n = 3). Below: Fluorescence images of anatomic tumors and other major organs (spleen, heart, liver, lung, and kidney) at 96 h after the intravenous injection of Dir@CaP-NPs and Dir@cRGD-CaP-NPs. b Quantitative analysis of the mean Dir fluorescence intensity of tumor sites of intravenous injection of Dir@CaP-NPs and Dir@cRGD-CaP-NPs for 2, 12, 24, and 96 h. Mean ± SEM, n = 3, **P < 0.01, ***P < 0.001. c Quantitative analysis of the mean Dir fluorescence intensity of the anatomic tumors and major organs (spleen, heart, liver, lung, and kidney) at 96 h after the intravenous injection of Dir@CaP-NPs and Dir@cRGD-CaP-NPs. d Schematic illustration of the MDA-MB-231 tumor implantation and the treatments in nude mice. Twenty days after tumor implantation, these mice were treated with the indicated treatments on the indicated days. e Fig. of tumors collected from the different treatment groups. f The tumor weights collected from different groups after anatomy (n = 6). g The tumor growth curves. h The changes of body weights